The results of this combined analysis demonstrated that patients carrying both the GSTP1 rs1695 AA and GSTO1 rs4925 CC genotypes had a significantly decreased risk of bladder cancer recurrence, when compared with the combined increased risk genotypes (the GSTP1 AG+GG genotype and the GSTO1 AC+AA genotype). The gene discussed is GSTO1; the disease is urinary bladder carcinoma.